Eiko Lifesciences Ltd

Eiko Lifescience has shown significant growth from March 2018 to March 2025, with net sales rising from 2.34 crore to 37.66 crore and profit after tax increasing from 0.20 crore to 2.18 crore, alongside a substantial rise in total assets. The company has improved operational efficiency, reflected in higher operating profit and earnings per share.

On 27-Nov, Eiko Lifesciences Ltd witnessed a decline in its share price, closing at ₹51.29 with a loss of 0.77%, reflecting a broader trend of underperformance relative to its sector and key technical indicators.

As of 17-Nov, Eiko Lifesciences Ltd's stock price is Rs 53.10, down 3.01%, and has underperformed the sector by 3.43%. The stock has shown significant volatility, with a year-to-date decline of 15.36%, contrasting with the Sensex's gain of 8.72%, indicating a challenging environment for the company.

Eiko Lifescience has demonstrated significant growth in net sales and profitability, with net sales increasing from 2.34 Cr in March 2018 to 37.66 Cr in March 2025, and a turnaround in profit from losses in 2020 to a net profit of 2.11 Cr in March 2025. The company's total assets also grew substantially, reflecting a strong recovery in its financial performance.

As of November 13, 2025, Eiko Lifescience is considered undervalued with an attractive valuation grade, featuring a PE ratio of 31.29, an EV to EBITDA of 30.99, and a PEG ratio of 0.32, which positions it favorably compared to peers like Bajaj Finance and Bajaj Finserv, despite recent underperformance against the Sensex.

As of 06-Nov, Eiko Lifesciences Ltd's stock price is Rs 57.49, down 7.32% after a trend reversal despite recent gains. The stock has shown high volatility and underperformed today, but has outperformed its sector over the past week and month.

As of 04-Nov, Eiko Lifesciences Ltd's stock price has risen to 62.03, marking a 7.99% increase and outperforming its sector. The stock has shown strong performance with a 22.4% return over the last four days and significant investor participation, indicating a positive trend.

Eiko Lifescience experienced significant growth from March 2018 to March 2025, with net sales rising from 2.34 Cr to 37.66 Cr, and a turnaround in profitability, achieving a profit after tax of 2.18 Cr in March 2025, compared to a loss of 3.62 Cr in March 2020. Total assets increased from 10.95 Cr to 66.10 Cr during the same period.

Eiko Lifesciences reported strong financial results for Q2 FY2025, with a 43.01% increase in net sales and a 285.71% rise in net profit, indicating positive growth. However, concerns remain regarding its low return on equity of 3.23%, highlighting challenges in capital efficiency.

As of 31-Oct, Eiko Lifesciences Ltd is seeing a price increase to Rs 56.50, up 7.25%, with strong short-term performance and positive trends in trading volumes. Despite a year-to-date decline, recent gains suggest a potential recovery and improved investor sentiment.

Eiko Lifescience has shown significant growth from Mar'18 to Mar'25, with net sales increasing from 2.34 Cr to 37.66 Cr, and profit after tax rising from 0.20 Cr to 2.18 Cr. The company's total assets grew from 10.95 Cr to 66.10 Cr, reflecting strong revenue and profitability improvements.

As of October 20, 2025, Eiko Lifescience is fairly valued with a PE ratio of 37.87, an EV to EBITDA of 32.38, and a PEG ratio of 0.61, indicating it may be more attractive relative to its growth potential compared to peers, despite a year-to-date return of -19.84% that has lagged behind the Sensex's 7.97%.

As of October 17, 2025, Eiko Lifescience is considered overvalued with a PE ratio of 38.40 and an EV to EBITDA of 32.90, significantly higher than its peers, and has underperformed with a year-to-date return of -18.73% compared to the Sensex's 7.44% gain.

As of October 17, 2025, Eiko Lifescience is considered overvalued with a PE ratio of 38.40 and an EV to EBITDA of 32.90, significantly higher than its peers, while also underperforming the market with a year-to-date return of -18.73%.